Protein array technology to investigate cytokine production by monocytes from patients with advanced alcoholic cirrhosis: An ex vivo pilot study

Hepatology Research

Volumn 39, Issue 7, 2009, Pages 706-715

  Tazi, Khalid A ^a,b   Quioc, Jean Jacques ^a,b   Abdel Razek, Wael ^a,c   Tellier, Zéra ^d   Guichard, Cécile ^a,b   Ogier Denis, Eric ^a,b   Lebrec, Didier ^a,b   Moreau, Richard ^a  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c MENOUFIA UNIVERSITY   (Egypt)

^d Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

Author keywords

Chemokines; Chronic liver disease; Cytokines; Human cytokine array; Monocytes; Pentoxifylline; Toll like receptors

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; RANTES; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; SEQUENCE HOMOLOGY;

EID: 67649625536     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00498.x     Document Type: Article

References (47)

1. Felver ME, Mezey E, McGuire M et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990; 14: 255-9.
2. McClain CJ, Cohen DA, Dinarello CA, Cannon JG, Shedlofsky SI, Kaplan AM. Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci 1986; 39: 1479-85.
3. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992; 119: 547-52.
4. Haukeland JW, Damas JK, Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-74.
5. Neuman MG, Benhamou JP, Marcellin P et al. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-36.
6. Mack CL. Serum cytokines as biomarkers of disease and clues to pathogenesis. Hepatology 2007; 46: 6-8.
7. Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: Possible role of Akt and IRAK-M. J Hepatol 2006; 45: 280-9.
8. Albillos A, Hera Ad Ade L, Reyes E et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: Amelioration with norfloxacin. J Hepatol 2004; 40: 624-31.
9. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-62.
10. Freudenberg MA, Ness T, Kumazawa Y, Galanos C. [The role of cytokines in endotoxic shock and in endotoxin hypersensitivity]. Immun Infekt 1993; 21: 40-4.
11. Gessani S, Testa U, Varano B et al. Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages. Role of LPS receptors. J Immunol 1993; 151: 3758-66.
12. Moreau R, Hadengue A, Soupison T et al. Clinical, hemodynamic and metabolic characteristics and ICU outcome of septic shock in patients with cirrhosis. Crit Care Med 1992; 20: 746-50.
13. Wong F, Bernardi M, Balk R et al. Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
14. Zeni F, Pain P, Vindimian M et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996; 24: 207-14.
15. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993; 187: 447-63.
16. Neuner P, Klosner G, Schauer E et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994; 83: 262-7.
17. Moller DR, Wysocka M, Greenlee BM et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997; 91: 197-203.
18. Wang ZM, Liu C, Dziarski R. Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J Biol Chem 2000; 275: 20260-7.
19. Zhang B, Kirov S, Snoddy J. WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33: W741-8.
20. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, et al. From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res 2006; 34: D354-7.
21. Dennis G Jr, Sherman BT, Hosack DA et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
22. Tazi KA, Bièche I, Paradis V et al. In vivo altered unfolded protein response and apoptosis in livers from lipopolysaccharide-challenged cirrhotic rats. J Hepatol 2007; 46: 1075-8.
23. Grivennikov SI, Tumanov AV, Liepinsh DJ et al. Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/ neutrophils: Protective and deleterious effects. Immun 2005; 22: 93-104.
24. Deviere J, Content J, Denys C et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990; 11: 628-34.
25. Riordan SM, Skinner N, Nagree A et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003; 37: 1154-64.
26. Baehr V, Döcke WD, Plauth M et al. Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: Role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitisation. Gut 2000; 47: 281-7.
27. Lin CY, Tsai IF, Ho YP et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007; 46: 816-26.
28. Jankovic D, Trinchieri G. IL-10 or not IL-10: That is the question. Nat Immunol 2007; 8: 1281-3.
29. Locksley RM, Killeen N, Lenardo MJ The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487-501.
30. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl. J Med 1998; 338: 436-45.
31. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-21.
32. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004; 21: 227-39.
33. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
34. Haskill S, Johnson C, Eierman D, Becker S, Warren K. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J Immunol 1988; 140: 1690-4.
35. Sirenko OI, Lofquist AK, DeMaria CT, Morris JS, Brewer G, Haskill JS. Adhesion-dependent regulation of an A+U-rich element-binding activity associated with AUF1. Mol Cell Biol 1997; 17: 3898-906.
36. Guamer C, Soriano G, Tomas A et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxaemia. Hepatology 1993; 18: 1139-43.
37. Wang SS, Lee FY, Chan CC et al. Sequential changes in plasma cytokine and endotoxin levels in cirrhotic patients with bacterial infection. Clin Sci (Lond) 2000; 98: 419-25.
38. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139: 186-93.
39. Albillos A, de la Hera A, González M et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
40. Morencos FC, de las Heras Castano G, Ramos M et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1995; 40: 1252-6.
41. Cirera I, Bauer TM, Navasa M et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.
42. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-41.
43. Tazi KA, Moreau R, Herve P et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: Role of Akt signaling. Gastroenterology 2005; 129: 303-14.
44. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
45. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
46. Le Moine O, Marchant A, De Groote D, Azar C, Goldman M, Deviere J. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 1995; 22: 1436-9.
47. Plessier A, Denninger MH, Consigny Y et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003; 23: 440-8.